(Q40896732)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26603202%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

title

L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26603202%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

0 references

1 reference

3

Hadas Dvory-Sobol

0 references

author name string

Evguenia S Svarovskaia

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26603202%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Edward Gane

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26603202%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Hadas Dvory-Sobol

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26603202%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Ross Martin

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26603202%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Brian Doehle

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26603202%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Charlotte Hedskog

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26603202%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Ira M Jacobson

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26603202%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

David R Nelson

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26603202%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Eric Lawitz

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26603202%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Diana M Brainard

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26603202%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

John G McHutchison

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26603202%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Michael D Miller

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26603202%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Hongmei Mo

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26603202%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

language of work or name

English

0 references

publication date

24 November 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26603202%20AND%20SRC:MED&resulttype=core&format=json

Journal of Infectious Diseases

1 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26603202%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

213

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26603202%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26603202%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

1240-1247

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26603202%20AND%20SRC:MED&resulttype=core&format=json

Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus

1 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV564

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV564

Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV564

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV564

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV564

Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV564

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV564

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV564

PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV564

Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV564

Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV564

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV564

Sofosbuvir for previously untreated chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV564

Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV564

Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV564

In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV564

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV564

21 January 2018

Identifiers

DOI

10.1093/INFDIS/JIV564

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26603202%20AND%20SRC:MED&resulttype=core&format=json

release_xoqgrmt6nfa6xg6adelpk4qrde

1 March 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xoqgrmt6nfa6xg6adelpk4qrde

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26603202%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

PubMed publication ID

26603202

1 reference